Arvinas will present novel biomarker data from a Phase 1 clinical trial of ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, taking place on 4-8 October 2026, with late-breaking oral and e-poster presentations scheduled for 7 October.
According to the company, the oral presentation is listed as session 12, Late-Breaking Abstracts: Parkinson’s Disease, presentation LBA 15, Conference Room E3 on the third floor, scheduled in the 12:30 to 13:30 ET session, and an e-poster will be available online.
The company describes ARV-102 as an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and target LRRK2, and the company claims ARV-102 has been evaluated in a Phase 1 trial in healthy volunteers and in patients with Parkinson’s disease.
The announcement also highlights Arvinas’ broader PROTAC pipeline, including ARV-393, ARV-027, ARV-6723 and ARV-806, and notes the company’s prior work with Pfizer that produced the first U.S. FDA-approved PROTAC, which has been outlicensed for global development.
